Cerebral Infarction Drugs Market Share

  • Report ID: 3382
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Cerebral Infarction Drugs Market Share

North American Market Forecast   

The North America industry is poised to hold largest revenue share of 50% by 2037. The growth of the market can be attributed majorly to the increasing frequency of cerebrovascular disease amongst several people, backed by the sedentary lifestyle of individuals. For instance, the fifth most common cause of mortality in the United States and the most frequent type of brain injury that poses a serious risk to life is a cerebrovascular disease which contributed to more than 168,000 deaths in 2020. In addition, the region's escalating healthcare industry, and rising proportion of obesity, and hypertension rates in the population of the United States and Canada are also anticipated to boost the market growth during the forecast period. In addition to this, the increasing approval for novel drug delivery systems and treatments is another significant factor that is projected to further boost the market growth in the region during the projected time frame.

APAC Market Statistics

The Asia Pacific cerebral infarction drugs market, amongst the market in all the other regions, is projected to hold the second largest share of about 20% during the forecast period. The growth of the market can be attributed majorly to the rising geriatric population, and the advancing healthcare system. Based on the statistics of the World Bank, the population above 65 years of age in India crossed 90,719,952 in 2020, while, it crossed 167,808,567 in China. Moreover, rising healthcare expenditure and surging investment in R&D activities is also estimated to boost the market growth further throughout the projected time frame in the APAC region.

Europe Market Forecast

Further, the market in the European region, amongst the market in all the other regions, is projected to hold a majority of the share of about 15% by the end of 2037. The growth of the market can be attributed majorly to the increasing frequency of hypertension, coupled with the escalating prevalence of atherosclerosis among people in the region. Further, the existence of a strong healthcare network in the region, along with the region's expanding healthcare industry, and rise in novel drug developments are also anticipated to boost the market growth during the forecast period. 

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3382
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cerebral infarction drugs is assessed at USD 8.64 billion.

The cerebral infarction drugs market size was valued at USD 7.61 billion in 2024 and is expected to reach USD 21.2 billion by 2037, expanding at around 8.2% CAGR during the forecast period i.e., between 2025-2037. Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes will boost the market growth.

North America industry is poised to hold largest revenue share of 50% by 2037, propelled by increasing frequency of cerebrovascular disease amongst several people, driven by sedentary lifestyle of individuals.

The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Edwards Lifesciences Corporation, Daiichi Sankyo Company, Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample